Prostatype Genomics AB (publ) (PGABF)
OTCMKTS · Delayed Price · Currency is USD
0.0850
-0.2734 (-76.28%)
At close: Jan 7, 2026
Prostatype Genomics AB Company Description
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests.
The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score.
Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision.
The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Prostatype Genomics AB (publ)
| Country | Sweden |
| Founded | 2007 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 6 |
| CEO | Fredrik Rickman |
Contact Details
Address: Gustaf III:s Boulevard 34 Solna, 169 73 Sweden | |
| Phone | 46 08 20 87 00 |
| Website | prostatypegenomics.com |
Stock Details
| Ticker Symbol | PGABF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Fredrik Rickman | Chief Executive Officer and MD |
| Anders Koch | Chief Financial Officer |
| George Skinner | Vice President Commercial operations |
| Emelie Berglund | Chief Technology Officer |
| Nicklas Rosendal | Communications Director |
| Joakim Soderin | Chief Auditor |
| Prof. Gerald L. Andriole Jr., M.D. | Global Chief Medical Officer |
| Steven Gaal | President of US operations |
| Katarina Sjöberg | QA and RA Manager |
| Mats Bergström | Sales Director of EMEA |